Cancer drug absorption tested with food and acid reducers
NCT ID NCT05468164
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This completed Phase 1 study enrolled 20 healthy adults to see how a high-fat meal and the acid-reducing drug omeprazole affect how the body absorbs selpercatinib, a cancer medication. Participants took selpercatinib under different conditions (with food, without food, and after omeprazole) to measure drug levels in the blood. The goal was to understand how these factors might change dosing recommendations for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion
Tempe, Arizona, 85283, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selpercatinib (a cancer drug) and omeprazole (a stomach acid reducer)
What this could lead to
If successful, this could help doctors give better dosing instructions for selpercatinib, potentially improving its effectiveness in cancer patients.
What could go wrong
This was a small, early-stage study in healthy people, not patients. Results may not directly apply to cancer patients or predict real-world outcomes.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.